142 related articles for article (PubMed ID: 35710239)
1. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial).
Lau SP; van 't Land FR; van der Burg SH; Homs MYV; Lolkema MP; Aerts JGJV; van Eijck CHJ
BMJ Open; 2022 Jun; 12(6):e060431. PubMed ID: 35710239
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
4. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP; van Montfoort N; Kinderman P; Lukkes M; Klaase L; van Nimwegen M; van Gulijk M; Dumas J; Mustafa DAM; Lievense SLA; Groeneveldt C; Stadhouders R; Li Y; Stubbs A; Marijt KA; Vroman H; van der Burg SH; Aerts J; van Hall T; Dammeijer F; van Eijck CHJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690771
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).
Wei M; Shi S; Hua J; Xu J; Yu X;
BMJ Open; 2019 Dec; 9(12):e033452. PubMed ID: 31818843
[TBL] [Abstract][Full Text] [Related]
8. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
Creemers JHA; Pawlitzky I; Grosios K; Gileadi U; Middleton MR; Gerritsen WR; Mehra N; Rivoltini L; Walters I; Figdor CG; Ottevanger PB; de Vries IJM
BMJ Open; 2021 Nov; 11(11):e050725. PubMed ID: 34848513
[TBL] [Abstract][Full Text] [Related]
9. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
Lau SP; Klaase L; Vink M; Dumas J; Bezemer K; van Krimpen A; van der Breggen R; Wismans LV; Doukas M; de Koning W; Stubbs AP; Mustafa DAM; Vroman H; Stadhouders R; Nunes JB; Stingl C; de Miranda NFCC; Luider TM; van der Burg SH; Aerts JG; van Eijck CHJ
Eur J Cancer; 2022 Jul; 169():20-31. PubMed ID: 35490565
[TBL] [Abstract][Full Text] [Related]
10. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Nakano S; Kawamoto Y; Yuki S; Harada K; Miyagishima T; Sogabe S; Dazai M; Sato A; Ishiguro A; Nakamura M; Kajiura S; Takahashi Y; Tateyama M; Hatanaka K; Tsuji Y; Sasaki T; Shindo Y; Kobayashi T; Yokota I; Sakamoto N; Sakata Y; Komatsu Y
BMJ Open; 2022 May; 12(5):e048833. PubMed ID: 35534074
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
12. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
13. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
de Boer NL; Brandt-Kerkhof ARM; Madsen EVE; Diepeveen M; van Meerten E; van Eerden RAG; de Man FM; Bouamar R; Koolen SLW; de Hingh IHJT; Bakkers C; Rovers KP; Creemers GM; Deenen MJ; Kranenburg OW; Constantinides A; Mathijssen RHJ; Verhoef C; Burger JWA; ;
BMJ Open; 2019 Dec; 9(12):e034508. PubMed ID: 31818845
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study.
Roth S; Springfeld C; Diener MK; Tjaden C; Knebel P; Klaiber U; Michalski CW; Mieth M; Jäger D; Büchler MW; Hackert T
BMJ Open; 2019 Aug; 9(8):e028696. PubMed ID: 31434770
[TBL] [Abstract][Full Text] [Related]
16. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma.
Ponzini FM; Schultz CW; Leiby BE; Cannaday S; Yeo T; Posey J; Bowne WB; Yeo C; Brody JR; Lavu H; Nevler A
BMJ Open; 2023 Oct; 13(10):e073839. PubMed ID: 37848297
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
van Kooten JP; Dietz MV; Guchelaar NAD; Brandt-Kerkhof ARM; Koolen SLW; Burger JWA; Mathijssen RHJ; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2022 Jun; 12(6):e062907. PubMed ID: 35732399
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
20. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol.
Vatandoust S; Bright T; Roy AC; Watson D; Gan S; Bull J; Abbas MN; Karapetis CS
BMJ Open; 2019 May; 9(5):e026732. PubMed ID: 31061042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
